Literature DB >> 24950013

Update on SPECT and PET in parkinsonism - part 1: imaging for differential diagnosis.

Philipp T Meyer1, Sabine Hellwig.   

Abstract

PURPOSE OF REVIEW: To give an update on recent findings concerning the use of single-photon emission computed tomography (SPECT) and positron emission tomography (PET) for differential diagnosis and prognosis of neurodegenerative parkinsonism and related disorders. RECENT
FINDINGS: Several studies confirmed the very high diagnostic accuracy and clinical impact of imaging nigrostriatal function (most notably with [I]FP-CIT-SPECT) for diagnosing neurodegenerative parkinsonism and dementia with Lewy bodies. Accurate differential diagnosis of neurodegenerative parkinsonism can be achieved by imaging disease-specific patterns of cerebral glucose metabolism with [18F]fluorodeoxyglucose-PET, which surpasses the diagnostic accuracy of other currently available radionuclide imaging techniques.
SUMMARY: SPECT and PET are established methods for the differential diagnosis of parkinsonism with significant therapeutic and prognostic impact. Given the limited accuracy of the clinical diagnosis as the reference standard, future studies with post-mortem verification are needed for validation of diagnostic imaging pattern, particularly in tauopathies.

Entities:  

Mesh:

Year:  2014        PMID: 24950013     DOI: 10.1097/WCO.0000000000000106

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  6 in total

Review 1.  Differentiation of atypical Parkinson syndromes.

Authors:  Günter U Höglinger; Jan Kassubek; Ilona Csoti; Reinhard Ehret; Heinz Herbst; Ingmar Wellach; Jürgen Winkler; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2017-02-27       Impact factor: 3.575

Review 2.  Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

Authors:  Chae-Moon Hong; Ho-Sung Ryu; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

3.  Chiral resolution of serial potent and selective σ1 ligands and biological evaluation of (-)-[18F]TZ3108 in rodent and the nonhuman primate brain.

Authors:  Xuyi Yue; Hongjun Jin; Zonghua Luo; Hui Liu; Xiang Zhang; Ethan D McSpadden; Linlin Tian; Hubert P Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu
Journal:  Bioorg Med Chem       Date:  2017-01-16       Impact factor: 3.641

Review 4.  Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies.

Authors:  Kirk A Frey
Journal:  Semin Nucl Med       Date:  2021-01-08       Impact factor: 4.446

Review 5.  SARS-CoV-2, COVID-19 and Parkinson's Disease-Many Issues Need to Be Clarified-A Critical Review.

Authors:  Tsepo Goerttler; Eun-Hae Kwon; Michael Fleischer; Mark Stettner; Lars Tönges; Stephan Klebe
Journal:  Brain Sci       Date:  2022-03-28

Review 6.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.